Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can brisk walking beat steady exercise for Women's heart health?

NCT ID NCT07370363

Knowledge-focused Sponsor: Havva Talay Çalış Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looks at how two different exercise programs affect a protein called Sestrin-2, which is linked to inflammation and metabolism, in women with obesity and high blood pressure. About 42 women aged 30-65 will do either moderate steady exercise or brisk interval exercise for 8 weeks. Researchers will measure changes in Sestrin-2 levels, fitness, and other heart health markers to learn which exercise type may be better.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 42 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Feb 2026

An estimate. Start dates often move.

Expected to finish

Aug 2026

An estimate. End dates often move.

Lead sponsor

A government agency

The lead sponsor is a government body.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

30 to 65 years

Sex

Female participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Female participants aged between 30 and 65 years * Body mass index between 30.0 and \<40.0 kg/m² (Class I and Class II obesity) * Diagnosis of hypertension according to the 2018 European Society of Hypertension/European Society of Cardiology (ESH/ESC) guidelines * Sedentary lifestyle, defined as total weekly exercise duration of less than 60 minutes * Medically eligible for exercise participation, with approval from a Physical Medicine and Rehabilitation specialist and an Internal Medicine specialist * Willingness to participate in the study and provision of written informed consent Exclusion Criteria: * Neuromuscular disorders, uncontrolled psychiatric diseases, or cognitive impairment limiting exercise participation * Congestive heart failure, unstable angina, or acute cardiac conditions including acute myocardial infarction, acute endocarditis, myocarditis, or pericarditis * Presence of uncontrolled systemic diseases, including: * Uncontrolled hypertension * Uncontrolled diabetes mellitus * Chronic liver failure * Chronic kidney disease or patients receiving dialysis * Chronic obstructive pulmonary disease or asthma * History or presence of malignancy * Acute infection at the time of enrollment * Acute peripheral vascular disease * Symptomatic severe aortic stenosis * Acute pulmonary embolism or pulmonary infarction * Use of systemic corticosteroids or immunosuppressive medications * Inability to comply with the study protocol or lack of cooperation * Refusal to participate in the study

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Hypertension are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

hypertensive disorder Obesity obesity disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Hypertension Obesity

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Kayseri City Hospital

    Kayseri, Kayseri, Turkey (Türkiye)

More trials for these conditions

Other studies related to the condition(s) this trial covers.